Coming Soon

A Phase 2/3 Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab Compared to Daratumumab, Lenalidomide, and Dexamethasone in Subjects with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

The purpose of this study is to see if etentamig is safe and to identify the optimal etentamig dose when combined with daratumumab in participants with Newly Diagnosed Multiple Myeloma (NDMM) who are not eligible for transplant.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Eben Lichtman
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Blood Conditions
Cancer (Multiple Myeloma)

IRB Number

25-2337

ClinicalTrials.gov

NCT07095452

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.